Chardan Capital Maintains Buy Rating on Ocular Therapeutix
Chardan Capital maintained its Buy rating on Ocular Therapeutix's stock with a price target of $23.00, implying an upside of 215.5% from the Oct 1 close of $7.29.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Chardan Capital maintains Ocular Therapeutix Buy and $23 price target
Chardan Capital maintained its Buy rating on Ocular Therapeutix and kept a $23.00/share price target, reported by Benzinga.